Physician profile
Gary C Doolittle
NPI 1316031982
$101,586.81
in general payments reported to CMS, 2019-2025
14 companies · $72.46 in 2025
The $72.46 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $12K · 2021: $1,965 · 2022: $5,117 · 2023: $142 · 2024: $4,870 · 2025: $72.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,600 · Travel and Lodging: $745 · Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,600.00 |
| Travel and Lodging | $744.53 |
| Food and Beverage | $740.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41,873.08 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $41,038.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $7,930.20 | 2019-2023 | |
| Iovance Biotherapeutics, INC. | $4,727.15 | 2024 | Amtagvi |
| Genentech, INC. | $3,230.00 | 2022 | |
| Novartis Pharma Ag | $1,965.00 | 2021 | |
| Celgene Corporation | $600.00 | 2022 | |
| Array Biopharma INC | $159.95 | 2022-2025 | Braftovi, Mektovi |
| Caris Mpi, INC. | $62.95 | 2025 | Mi Cancer Seek |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Doolittle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.